A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.

Ha, Huan T; Lee, Julia S; Urba, Susan; Koenig, Ronald J; Sisson, James; Giordano, Thomas; Worden, Francis P

Ha, Huan T; Lee, Julia S; Urba, Susan; Koenig, Ronald J; Sisson, James; Giordano, Thomas; Worden, Francis P.

Affiliation

Ha HT; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.

Thyroid ; 20(9): 975-80, 2010 Sep.

Article in En | MEDLINE | ID: mdl-20718683

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma/drug therapy; Piperazines/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Pyrimidines/therapeutic use; Thyroid Neoplasms/drug therapy; Aged; Antineoplastic Agents/adverse effects; Benzamides; Carcinoma/radiotherapy; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines/adverse effects; Protein Kinase Inhibitors/adverse effects; Pyrimidines/adverse effects; Receptors, Platelet-Derived Growth Factor/analysis; Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Thyroid Neoplasms / Carcinoma / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Thyroid Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google